IPO11 knockdown also reduced engraftment of primary AML cells in secondary transplants, further demonstrating the importance of IPO11 for the viability of AML stem cells (Fig. 3h, Supplementary Fig. S4) Thus, inhibiting IPO11 targets AML progenitors and stem cells, including those from relapsed patients. This evidence concerns the gene IPO11 and acute myeloid leukemia.